Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
Krish Patel,Julie M. Vose,Sunita D. Nasta,Jennifer R. Brown,Kami J. Maddocks,Jennifer A. Woyach,Nirav N. Shah,Bita Fakhri,Benoît Tessoulin,Shuo Ma,Deepa Jagadeesh,Ewa Lech‐Marańda,Catherine C. Coombs,Manish Patel,Joanna Rhodes,Chaitra S. Ujjani,Marc Hoffmann,Chan Y. Cheah,Talha Munir,David John Lewis